Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12104/41164
Título: Efficiency of rapd, issr, aflp and istr markers for the detection of polymorphisms and genetic relationships in camote de cerro (dioscorea spp.)
Autor: Ramirez-Ramirez, V.
Macias-Islas, M.A.
Ortiz, G.G.
Pacheco-Moises, F.
Torres-Sanchez, E.D.
Sorto-Gomez, T.E.
Cruz-Ramos, J.A.
Orozco-Avina, G.
Celis De La Rosa, A.J.
Fecha de publicación: 2013
Resumen: Multiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue injury in the central nervous system. Oxidative stress is also thought to promote tissue damage in multiple sclerosis. Current research findings suggest that omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapenta-enoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have anti-inflammatory, antioxidant, and neuroprotective effects. The aim of the present work was to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokine levels, oxidative stress markers, and disease progression in MS. 50 patients with relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish oil for 12 months. The primary outcome was serum TNF? levels; secondary outcomes were IL-1? 1b, IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status scale (EDSS), and annualized relapses rate (ARR). Fish oil treatment decreased the serum levels of TNF?, IL-1?, IL-6, and nitric oxide metabolites compared with placebo group (P?0.001). There was no significant difference in serum lipoperoxide levels during the study. No differences in EDSS and ARR were found. Conclusion. Fish oil supplementation is highly effective in reducing the levels of cytokines and nitric oxide catabolites in patients with relapsing-remitting MS. " 2013 V. Ramirez-Ramirez et al.",,,,,,"10.1155/2013/709493",,,"http://hdl.handle.net/20.500.12104/41164","http://www.scopus.com/inward/record.url?eid=2-s2.0-84880179627&partnerID=40&md5=d05323ee095abeb7cb5a928d230bf7cf",,,,,,,,"Oxidative Medicine and Cellular Longevity",,,,,,"Scopus
WOS",,,,,,,,,,,,"Efficacy of fish oil on serum of TNF ?, IL-1 ?, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b",,"Article" "42944","123456789/35008",,"Rodriguez-Noriega, E., Division of Infectious Diseases, Universidad de Guadalajara, Guadalajara, Mexico; Quintero, N.P., Division of Infectious Diseases, Universidad de Guadalajara, Guadalajara, Mexico; Rodriguez Chagollan, J.J., Division of Infectious Diseases, Universidad de Guadalajara, Guadalajara, Mexico; Covarrubias, R., Division of Infectious Diseases, Universidad de Guadalajara, Guadalajara, Mexico; García, A., Division of Infectious Diseases, Universidad de Guadalajara, Guadalajara, Mexico",,"Rodriguez-Noriega, E.
Quintero, N.P.
Rodriguez Chagollan, J.J.
Covarrubias, R.
García, A.",,"1990",,"This double-blind study was performed in 122 patients with streptococcal tonsillitis pharyngitis. Ninety-five patients were considered in the final evaluation; the other 27 patients were not evaluable because of negative culture at baseline. The 95 patients were treated with 1,200 mg of lincomycin intramuscular (IM) once a day (46 patients, group A) or 600 mg of lincomycin twice a day (49 patients, group B) for ten days. There were no significant differences between the groups at baseline regarding demographic data, signs, symptoms, culture results, or laboratory evaluation. The mean number of days to become afebrile was 1.28 and the mean number of days for a reduction of at least 50% in signs and symptoms was 2.21. Significant differences in achieving a negative culture were noted by the third day for both groups. In group A, 95.7% of the patients were cured; in group B, 91.8% were cured. After a one-month follow-up evaluation, we found 2.2% of the patients were carriers. The adverse reaction reported was pain on IM injection. In conclusion, the efficacy and tolerance of lincomycin once a day was identical to that of lincomycin twice a day, and the carrier and rence rates were lower than with other antibiotics.",,,,,,,,,"http://hdl.handle.net/20.500.12104/41165","http://www.scopus.com/inward/record.url?eid=2-s2.0-0025306504&partnerID=40&md5=0f24519d042a6ff0fa523a9db4b321e1",,,,,,"3",,"Current Therapeutic Research - Clinical and Experimental",,"571
583",,"47",,"Scopus
WOS",,,,,,,,,,,,"Efficacy of intramuscular lincomycin 600 mg twice daily versus lincomycin 1.2 gm once daily in the treatment of acute tonsillitis/pharyngitis in adults",,"Article" "42945","123456789/35008",,"Gonzalez-Lopez, L., Dept. of Int. Med. - Rheumatology, Hospital General Regional 110, IMSS, Guadalajara, Mexico, Ave. Salto del Agua 2192, Guadalajara, Jalisco CP 44210, Mexico; García-Gonzalez, A., Sect. Musculoskel. Dis./Autoimmunity, Clinical Epidemiology Research Unit, HECMNO, Mexico; Vazquez-Del-Mercado, M., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Muñoz-Valle, J.F., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Gamez-Nava, J.I., Sect. Musculoskel. Dis./Autoimmunity, Clinical Epidemiology Research Unit, HECMNO, Mexico",,"Gonzalez-Lopez, L.
García-Gonzalez, A.
Vazquez-Del-Mercado, M.
Munoz-Valle, J.F.
Gamez-Nava, J.I.",,"2004",,"Objective. To evaluate the efficacy and safety of methotrexate (MTX) compared with placebo in patients with active ankylosing spondylitis (AS). Methods. This 24 week, double bind, randomized, placebo controlled trial compared the response between MTX 7.5 mg/week or placebo in patients with active AS. The primary outcome measure was a composite index of improvement in 5 of the following scales: severity of morning stiffness, physical well being, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S), and physician and patient global assessment of disease activity. Results. Seventeen patients received MTX and 18 placebo. In the intention-to-treat analysis at 24 weeks, 53% of patients in the MTX group had a treatment response, compared with 17% in the placebo group (p = 0.03). We observed significant improvements with MTX in physical well being (p = 0.009), BASDAI (p = 0.02), BASFI (p = 0.02), physician global assessment (p < 0.001), patient global assessment (p = 0.03), and HAQ-S (p = 0.02). In the adjusted analysis only MTX determined the improvement in the primary outcome. At the end of the trial, one patient with MTX withdrew due to a lack of compliance, and one with placebo due to a lack of efficacy. We did not observe significant differences in rates of side effects between the 2 groups. Conclusion. MTX is safe and effective for patients with AS. Longterm studies are needed to evaluate the permanence of its benefit.",,,,,,,,,"http://hdl.handle.net/20.500.12104/41166","http://www.scopus.com/inward/record.url?eid=2-s2.0-3442880132&partnerID=40&md5=bc16a966315a33e0191832b64efea3d9",,,,,,"8",,"Journal of Rheumatology",,"1568
1574",,"31",,"Scopus
WOS",,,,,,"Ankylosing spondylitis; Methotrexate; Randomized controlled trial",,,,,,"Efficacy of methotrexate in ankylosing spondylitis: A randomized, double blind, placebo controlled trial",,"Article" "42946","123456789/35008",,"Velasco-Ramírez, A.P., Instituto de Manejo y Aprovechamiento de Recursos Fitogenéticos, Universidad de Guadalajara, Km. 15.5 Carr. Guadalajara-Nogales, Zapopan, Jalisco, Mexico; Torres-Morán, M.I., Instituto de Manejo y Aprovechamiento de Recursos Fitogenéticos, Universidad de Guadalajara, Km. 15.5 Carr. Guadalajara-Nogales, Zapopan, Jalisco, Mexico; Molina-Moret, S., Fundación Instituto de Estudios Avanzados, Centro Nacional de Biotecnología agrícola, Carretera Nacional de Hoyo de la Puerta, Valle Sartenejas, Baruta. Edo, Miranda, Caracas 1015-A, Venezuela; de Jesús Sánchez-González, J., Instituto de Manejo y Aprovechamiento de Recursos Fitogenéticos, Universidad de Guadalajara, Km. 15.5 Carr. Guadalajara-Nogales, Zapopan, Jalisco, Mexico; Santacruz-Ruvalcaba, F., Instituto de Manejo y Aprovechamiento de Recursos Fitogenéticos, Universidad de Guadalajara, Km. 15.5 Carr. Guadalajara-Nogales, Zapopan, Jalisco, Mexico",,"Velasco-Ramirez, A.P.
Torres-Moran, M.I.
Molina-Moret, S.
de Jesus Sanchez-Gonzalez, J.
Santacruz-Ruvalcaba, F.",,"2014",,"Background: At present, species known as camote de cerro (Dioscorea spp.) are found only in the wilderness in Mexico, but their populations are extremely depleted because they are indiscriminately collected, it is urgent to evaluate the conservation status of these plants in order to design conservation genetics programs. In this study, genetic diversity parameters along with cluster analysis based on Jaccard's coefficient were estimated 16 with the objective to assess the efficiency of RandomAmplified Polymorphic DNA (RAPD), Inter Simple Sequence Repeat (ISSR), Amplified Fragment Length Polymorphism (AFLP) and Inverse Sequence Tagged Repeat (ISTR) molecular DNA markers in the Dioscorea genus. Results: The polymorphic information contents were quite similar for all markers (?0.48). Genetic variation of Dioscorea spp., in terms of average heterozygosity was lower with ISTR (0.36), and higher when other markers were used (RAPD = 0.43; ISSR = 0.45 and AFLP = 0.47). Conclusion: This indicates an important level of genetic differences despite the fact that the plant is asexually propagated. Based on the diversity statistics, any marker tested in present work can be recommended for use in large-scale genetic studies of populations. However, the low correlations among different molecular marker systems show the importance of the complementarity of the information that is generated by different markers for genetic studies involving estimation of polymorphism and relationships. " 2014 Pontificia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. All rights reserved.
URI: http://hdl.handle.net/20.500.12104/41167
http://www.scopus.com/inward/record.url?eid=2-s2.0-84896330347&partnerID=40&md5=062ac41a5c2fed47f02408dbe92b50b9
Aparece en las colecciones:Producción científica UdeG

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de RIUdeG están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.